Could a lupus drug unlock kidney transplants for Hard-to-Match patients?
NCT ID NCT07539857
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a short course of belimumab, a drug used for lupus, can improve detection of immune cells that cause transplant rejection. The goal is to help highly sensitized kidney transplant candidates—people whose immune systems are very picky about donor organs—get matched faster. Twenty-five adults will receive belimumab and provide blood samples to see if it changes their immune profile and leads to more donor offers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belimumab (Benlysta)
What this could lead to
If successful, this could help highly sensitized kidney transplant candidates get donor organs faster and more safely by improving immune matching.
What could go wrong
This is a small, early-phase study with only 25 participants, so results may not apply broadly. Belimumab may not effectively mobilize the targeted cells, and the approach may not improve transplant access.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Leiden University Medical Centre
Leiden, 2333 ZA, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••